Ken Griffin
ONCR

Ken Griffin’s Oncorus, Inc. ONCR Stock Holding History

Ken Griffin’s Portfolio ONCR Stock Details ONCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-25,999
Closed -$8.95K – 15632
2023
Q1 		$8.95K Sell
25,999
-1,898,423
-99% -$708K ﹤0.01% 13616
2022
Q4 		$487K Buy
1,924,422
+9,828
+0.5% +$5.59K ﹤0.01% 8298
2022
Q3 		$1.63M Buy
1,914,594
+23,002
+1% +$29.5K ﹤0.01% 5991
2022
Q2 		$2.38M Buy
1,891,592
+3,123
+0.2% +$4.24K ﹤0.01% 5205
2022
Q1 		$3.36M Sell
1,888,469
-2,140
-0.1% -$6K ﹤0.01% 4949
2021
Q4 		$9.96M Buy
1,890,609
+8,099
+0.4% +$62.7K ﹤0.01% 3084
2021
Q3 		$17.6M Sell
1,882,510
-18,460
-1% -$211K ﹤0.01% 2197
2021
Q2 		$26.2M Buy
1,900,970
+7,935
+0.4% +$123K 0.01% 1761
2021
Q1 		$26.4M Buy
1,893,035
+13,698
+0.7% +$284K 0.01% 1645
2020
Q4 		$60.8M Buy
+1,879,337
New +$43.5M 0.02% 821

Other funds holding ONCR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
YAL
Your Advocates Ltd Houston, Texas $350M AUM 21.03% 1-Year Est. Return

Ken Griffin's ONCR Position: Q2 2023 in Review

Ken Griffin sold out of Oncorus, Inc. (ONCR) in Q2 2023, closing a stake of 25,999 shares — an estimated $8.95K sold.

Ken Griffin first reported a position in ONCR in Q4 2020 and held it in 10 quarters. The position peaked at $60.8M in Q4 2020. 4 funds tracked by Wall St. Rank hold ONCR as of Q2 2023.

  • Ken Griffin reported no remaining Oncorus, Inc. position as of Q2 2023 after selling out during the quarter.
  • Ken Griffin sold 25,999 Oncorus, Inc. shares in Q2 2023, an estimated $8.95K.
  • Ken Griffin first reported a position in Oncorus, Inc. in Q4 2020 and held it in 10 quarters.
  • Ken Griffin's Oncorus, Inc. position peaked at $60.8M in Q4 2020.
  • 4 funds tracked by Wall St. Rank held Oncorus, Inc. as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.